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Peripheral neuropathies, characterized by altered nociceptive and muscular functions, are
related to oxidative stress. Thioctic acid is a natural antioxidant existing as two optical
isomers, but most clinically used as racemic mixture. The present study investigated the
central nervous system’s changes which followed loose-ligation-derived compression of
sciatic nerve, the putative neuroprotective role of thioctic acid and the pain-alleviating effect
on low-back pain suffering patients. Loose ligation of the right sciatic nerve was performed
in spontaneously hypertensive rats (SHR), a model of increased oxidative stress, and in
normotensive Wistar-Kyoto rats (WKY). Animals with sciatic nerve ligation were left
untreated or were treated intraperitoneally for 15 days with 250 μmol·kg−1·die−1 of
(+/−)-thioctic acid; 125 μmol·kg−1·die−1 of (+/−)-thioctic acid; 125 μmol·kg−1·die−1 of
(+)-thioctic acid lysine salt; 125 μmol·kg−1·die−1 of (−)-thioctic acid; 300 μmol·kg−1·die−1
pregabalin. Control SHR and WKY rats received the same amounts of vehicle. The clinical
trial NESTIORADE (Sensory-Motor Neuropathies of the Sciatic Nerve: Comparative
evaluation of the effect of racemic and dextro-rotatory forms of thioctic acid) examined
100 patients (49 males and 51 females aged 53 ± 11 years) dividing them into two equal-
numbered groups, each treated daily for 60 days with 600 mg of (+/−)-thioctic acid or
(+)-thioctic acid, respectively. The trial was registered prior to patient enrollment at
EudraCT website (OSSC Number: 2011-000964-81). In the preclinical study,
(+)-thioctic acid was more active than (+/−)- or (−)-enantiomers in relieving pain and
protecting peripheral nerve as well as in reducing oxidative stress and astrogliosis in the
spinal cord. Main findings of NESTIORADE clinical trial showed a greater influence on
painful symptomatology, a quicker recovery and a better impact on quality of life of
(+)-thioctic acid vs. (+/−)-thioctic acid. These data may have a pharmacological and
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pharmacoeconomical relevance and suggest that thioctic acid, above all (+)-enantiomer,
could be considered for treatment of low-back pain involving neuropathy.
Keywords: neuropathic pain, thioctic acid, antioxidant, food supplement, neuroprotection
INTRODUCTION
Neuropathic pain is a form of chronic pain caused by lesions to
central or peripheral nervous system, which may be consequent
to mechanical damage or diseases. It is characterized by altered
nociceptive threshold and pain response, resulting in allodynia
and hyperalgesia (Riego et al., 2018). The lumbosacral syndrome
is a frequent neuropathic pathology described by a strong low
back pain which may come from damage or irritation of sciatic
nerve roots (Delitto et al., 2012). Treatment of its symptoms is
still debated: the comparative evaluation of efficacy and
tolerability of different drug categories (anti-inflammatory
drugs, corticosteroids, antidepressants, anticonvulsants, muscle
relaxants and opioids), concludes that most of the analyzed
studies are poor quality and the data insufficient to provide
guidance in the long-term treatment of the disease (Pinto
et al., 2012; Schnitzer et al., 2004).
The excessive and unbalanced presence of reactive oxygen
and nitrogen species causes oxidative stress, which alters the
structure of the biomolecules and consequently induces
neuronal damage (Adibhatla and Hatcher, 2010),
inflammatory events and negative loop of excitotoxicity of
afferent nociceptors, thus contributing to pain chronicization.
Antioxidant agents, like thioctic (alpha-lipoic) acid, proved a
therapeutic potential against neuropathy (Shay et al., 2009;
Oyenihi et al., 2015).
Thioctic acid is a natural substance, synthetized de novo in
mammalian mitochondria and existing as two optical isomers
(+)-, endogenously produced and biologically active, and
(−)-enantiomers. Racemic (+/−)-thioctic acid is sold
worldwide as a registered drug or in nutraceutical market as
dietary supplement and was reported to be a valid
pharmacological agent in treating oxidative stress related
diseases (Packer et al., 1995; Vasdev et al., 2000; Gomes and
Negrato, 2014). Clinical studies showed that treatments with
the racemic compound were able to reduce neuropathic low
back pain (Memeo and Loiero, 2008; Ranieri et al., 2009). Even
if the racemic mixture is the most widely used because of its
stability, recent studies developed salt derivatives of
(+)-thioctic acid with enough stability for a therapeutic use
on its own (Ranieri et al., 2009; Amenta et al., 2010).
Comparative studies revealed that (+)-thioctic acid displays
a more pronounced activity than the racemic (+/−)-thioctic
acid in several preclinical paradigms (Amenta et al., 2010;
Lokhandwala, 2010). In the present study, we aimed to
investigate if the (+)-thioctic acid is more active than its
racemic congener on painful symptoms of sensory-motor
neuropathies of the sciatic nerve in both a preclinical and
clinical setting. The strain of spontaneously hypertensive rats
(SHR), genetically harbouring hypertension and oxidative
stress, was chosen and underwent to the loose ligation of
the sciatic nerve (Tayebati et al., 2012). Pain relieving as
well as neuroprotective and antioxidant effects of thioctic
acid forms were compared to those of the reference drug
pregabalin, a currently in-use anticonvulsant for treating
chronic pain (Gilron et al., 2015; Xu et al., 2016). Based on
the evidence from preclinical study, a clinical trial, named
NESTIORADE (Sensory motor neuropathy of the sciatic
nerve: Comparative assessment of the effectiveness of





Twenty-week-old male SHR (n  42) and age-matched WKY
(n  42) rats were used. The animals were kept at 23 ± 1 °C with
a 12 h light/dark cycle, light at 7 a.m. and fed with standard
laboratory diet and tap water ad libitum. 24 h before the test,
the animals were placed in the experimental room for
acclimatization. All animal manipulations were carried out
according to the Directive 2010/63/EU of the European
Parliament and of the European Union council (September
22, 2010, amended by Regulation (EU) 2019/1010) on the
protection of animals used for scientific purposes and to the
ethical guidelines of the University of Florence, consistent with
the Guide for the Care and Use of Laboratory Animals of the
US National Institutes of Health (NIH Publication No. 85-23,
revised 1996; University of Florence assurance number:
A5278-01). Formal approval to conduct the experiments
described was obtained from the Italian Ministry of Health
and from the Animal Subjects Review Board of the University
of Florence. Experiments involving animals were reported
according to ARRIVE guidelines. All efforts were made to
minimize animal suffering and to reduce the number of
animals used.
Peripheral Mononeuropathy Rat Model
Neuropathy was induced in rats anaesthetized with 400 mg/kg
chloral hydrate intraperitoneally (i.p.) Chronic Constriction
Injury (CCI), according to the procedure described by
(Bennett and Xie, 1988). Under aseptic conditions, the right
common sciatic nerve was exposed at the level of the middle
thigh by blunt dissection and four chromic cat gut ligatures (4-
0, Ethicon, Norderstedt, Germany) were tied loosely around
the nerve with about 1 mm spacing. After that hemostasis was
confirmed, incision was closed in layers. After a period of
recovery from surgery, animals were housed one per cage with
free access to water and standard laboratory chow. Control
animals were sham operated.
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Animal Treatment
Thioctic acid, as (+/−)-compound, lysine salt (+)-enantiomer
and (−)-enantiomer, was pursued from Sintactica (Milan,
Italy). Compounds were solubilized in NaOH-supplemented
physiologic solution and buffered to 7.4 pH by adding HCl.
Different racemic and thioctic acid salt compounds were
solubilized in saline and injected intraperitoneally (i.p.).
Rats were treated for 15 days with intraperitoneal injection
of 250 μmol·kg−1·die−1 (+/−)-thioctic acid (n  6);
125 μmol·kg−1·die−1 (+/−)-thioctic acid (n  6);
125 μmol·kg−1·die−1 (+)-thioctic acid lysine salt (n  6);
125 μmol·kg−1·die−1 (−)-thioctic acid (n  6);
300 μmol·kg−1·die−1 pregabalin (n  6). Control CCI and
SHAM (operated without ligating sciatic nerve) SHR and
WKY rats (n  6 each) received the same amounts of vehicle.
To note, 250 μmol·kg−1·die−1 thioctic acid lysine salt
(+)-enantiomer (about 90 mg/kg) can be converted in the
human dosage of 569 mg (considering 70 kg body weight)
accordingly to Reagan-Shaw et al. (2008) and Nair and Jacob
(2016) using the equation [(rat dose mg kg−1/12.3) x 70].
Paw Pressure Test
One hour after the last drug administration, the nociceptive
threshold was determined with an analgesimeter (Ugo Basile,
Varese, Italy) (Leighton et al., 1988). A constantly increasing
pressure was applied by a mechanical device to a small area of
the dorsal surface of the paw, using a blunt conical probe.
Mechanical pressure was increased until vocalization or a
withdrawal reflex occurred while rats were lightly restrained.
Vocalization or withdrawal reflex thresholds were expressed in
grams. Rats scoring below 40 g or over 75 g during the test
before drug administration (25%) were discarded. An arbitrary
cut-off value of 250 g was adopted. The paw pressure test was
repeated in a second session at 24 h after the first experiments.
Tissue Processing
One hour after completion of the paw pressure test, animals were
sacrificed by cervical dislocation. The right sciatic nerve, was exposed,
excised and the portion containing the ligature was removed. Contra-
lateral nerves were also dissected out and a portion equivalent to that
of ligated nerve was removed.
Paraffin Embedding and Staining
After animal sacrifice, sciatic nerves were fixed in situ with 4%
formalin in phosphate buffered saline (pH 7.4). Following gradual
dehydration in ethanol, nerve samples were embedded in paraffin
(Diapath, Milan, Italy). Transverse 10 µm sections were cut on a
microtome (Leica, RM 2145), and mounted on polylysine coated
slides.
Sciatic Nerve Analysis: Histochemistry and
Immunohistochemistry
Consecutive paraffin sections (10 µm thick) were stained
alternatively with Mallory’s trichrome staining, to
investigate morphology of different nerve components and
occurrence of oedema and inflammatory infiltrates, or
processed for immunohistochemistry techniques. Oedema
and infiltrate were graded by an arbitrary scale starting
from 1, mild infiltrate and oedema up to 10, severe
infiltrate and widespread oedema. Sections were processed
for 200 kDa neurofilament protein (NF) immunoreactivity,
for Myelin Basic protein (MBP) or Glial fibrillary acidic
protein (GFAP) immunohistochemistry using a mouse
monoclonal antibody, as detailed in Table 1. Briefly, after
deparaffinization and rehydration, sections were incubated in
H2O2 3% for 20 min, and in a blocking solution of bovine
serum albumin (BSA) in phosphate buffer saline (PBS) 0.1 M
pH 7.4 for 1 h at room temperature. Incubation with primary
antibodies was performed over night at 4 °C at condition
detailed in Table 1. After three washes in PBS, sections were
incubated in a goat antimouse-biotinylated secondary
antibody. The product of the immune reaction was
revealed using a biotin–streptavidin immunostaining kit
(Vectastain ABC Kit Elite, Vector, Cat. No. PK 6100) and
3.3′-diamino benzidine (DAB) as a chromogen (DAB
peroxidase substrate, Vector Cat. No 4100). After washing,
sections were then dehydrated in ethanol, mounted in
mounting medium and observed under a light microscope.
Control sections were processed in the same way but using a
non-immune mouse IgG instead of the primary antibody.
These sections did not develop specific immunostaining (data
not shown). Sections processed for immunohistochemistry
were viewed under a light microscope connected to the screen
of IAS 2000 image analyzer. The intensity of axonal NF
immunostaining and the intensity of MBP immunostaining
developed in myelin sheaths were assessed microdensitometrically
with an image analysis system, calibrated to take as “zero” the
background developed in sections incubated with a non-immune
serum and “100” as the conventional value of maximum intensity of
staining.
TABLE 1 | Primary antibodies used in immunohistochemistry.
Primary antibody Company Cat. No. Dilution IHC
Anti-neurofilament 200kDa, clone RT-97 (NF) Monoclonal antibody, Merck-Millipore (Cat. No. MAB5262) 1:500
Anti-myelin basic protein (MBP) Monoclonal antibody, Merck-Millipore (Cat. No. NE1019) 1:500
Anti-glial fibrillary acidic protein (GFAP) Monoclonal antibody, Merck-Millipore USA (Cat. No. MAB3402) 1:500
Anti-8-OHdG Monoclonal antibody clone 2E2, Trevigen (Cat. No. 4354-MC-050) 1:250
Anti-mouse biotinylated Polyclonal antibody, Merck-Millipore (Cat. No. AP124B) 1:200
Anti-mouse Alexa fluor 488®, CellSignaling technology (Cat. No. #4408S) 1:100
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Spinal Cord Analysis: Malondialdehyde (MDA) Levels
and DNA Oxidation Status
In portions of spinal cord, oxidative stress indicators were
evaluated: malondialdehyde (MDA) levels via thiobarbituric
acid reactive substances (TBARS) kit (Cayman, Chemical
Company, Ann Arbor, MI, United States Cat. No.
10009055); DNA oxidation by 8-OHdG
immunohistochemistry. Paraffin sections of spinal cord
were processed for 8-OHdG immunohistochemistry, using
monoclonal antibodies as detailed Table 1. After
deparaffinization and rehydratation, sections were incubated
in a blocking solution of bovine serum albumin (BSA) in
phosphate buffer saline (PBS) 0.1 M pH 7.4 for 1 h at room
temperature. Incubation with primary antibodywas performed
over night at 4°Cat condition detailed in Table 1. After three
washes in PBS, sections were incubated in a biotinylated
secondary antibody solution (Table 1).
Protein Oxidation Status: Western Blot Analysis of
Carbonylated Proteins
Samples of spinal cord, taken from six rats for each group, were
homogenized in lysis buffer, as previously described (Tayebati
et al., 2017). We assessed protein carbonylation by treating equal
amounts of protein according to protocol of OxyBlot Protein
detection kit (Millipore, USA, Cat. No. S7150). The kit provides a
system to perform the immunoblot detection of carbonyl groups
introduced into proteins by oxidative reactions. As a
consequence, carbonyl groups are introduced into the side
chains of all proteins independently of the molecular weight.
The samples were separated by 8% SDS polyacrylamide gel,
transferred onto nitrocellulose and blotted with the specific
antibodies of the kit that recognize all the oxidized protein
with different molecular weight. Band intensities were
measured by densitometry with IAS 2000 image analyzer
(Biosystem, Rome, Italy).
Clinical Study
NESTIORADE is a comparative open trial, approved by the
Ethic Committee of “Azienda Ospedaliera Universitaria
Maggiore della Carità, Novara” and “Aziende Sanitarie
Locali” of Novara, Biella, Vercelli and Verbano Cusio Ossola
(NEST 2009) and written informed consent was obtained from
all subjects participating in the trial. The trial was registered
prior to patient enrollment at https://eudract.ema.europa.eu
(OSSC Number: 2011-000964-81; principal investigator: Prof.
Francesco Pipino; date of registration: February 28, 2011). The
study recruited 100 patients (49 males and 51 females, with a
mean age of 53 ± 11 years) who met criteria for inclusion and
agreed to participate at the trial. The number of participants
were chosen to ensure a minimum statistical power of 90% and
alpha of 5%, considering variance and effect of primary
outcomes. Patients were divided by block randomization
using a random generation number into two different groups
of 50 subjects each and were assigned to a 600 mg/day treatment
with (+/−)-thioctic acid (Group 1), or to a 600 mg/day
treatment with (+)-thioctic acid (Group 2). Treatments lasted
60 days. Study was not controlled by placebo due to a request of
the ethic committee, that did not allow to keep patients without
therapy during pain condition. (+/−)-thioctic acid therapy was
considered safe, effective and a good reference thanks to
publications that highlighted the efficacy and safety of its use
in similar pathologies (Memeo and Loiero, 2008; Ranieri et al.,
2009).
Inclusion criteria were:
• Radiculopathy of the lower limbs,
• Diagnosis confirmed by CT or MRI,
• Unilateral or bilateral presentation,
• First event,
• Onset of symptomatology not exceeding 40 days.
Exclusion criteria were:
• Cognitive deficits or psychiatric disorders,
• Specific indication for surgical treatment of
symptomatology,
• Poor compliance toward inclusion in the study,
• Concomitant neoplastic pathology,
• Chemotherapy or immunosuppressive treatment ongoing,
• Under treatment with thioridazine hydrochloride.
The evaluation of time loss/disappearance of symptoms was
performed by using multidimensional scales designed for
neuropathic pain (Xiong et al., 2015) listed below:
(1) Neuropathy Symptoms and Change (NSC) (Dyck et al.,
2002);
(2) Neuropathy Impairment Score (NIS) (Dyck et al., 2002);
(3) Neuropathic Total Symptom Score-6 (NTSS-6) (Bastyr et al.,
2005).
To better assess the impact of the compared treatments on life
quality of patients, the following parameters were evaluated:
(1) Consumption of analgesics during the whole treatment
period;
(2) Quality of sleep.
This manuscript adheres to the applicable CONSORT
guidelines. (Figure 1).
Statistical Analysis
All data of different parameters were expressed as mean ± S.D.
(n  6), calculated from single animal data. The significance of
differences between groups of treatment was analyzed by analysis
of variance (ANOVA) followed by the Newman-Keuls test, while
for the analysis of the differences within the group over time,
Student’ t-test for paired data were performed. For analyzing the
different treatment over time a two way ANOVA for repeated
measure was used. X-squared (X2) test was performed to evaluate
differences in qualitative data. Data were collected by researchers
blind to the treatments.
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CCI SHR and CCI WKY rats were treated intraperitoneally (i.p.)
for 15 days with (+/−)-thioctic acid (125–250 μmol·kg−1·die−1)
(+)-thioctic acid (125 μmol·kg−1·die−1), (−)-thioctic acid
(125 μmol·kg−1·die−1) or pregabalin (300 μmol·kg−1·die−1),
starting on the day of the surgery. Likewise, control SHAM and
CCI animals were treated i. p. with vehicle (data not shown). At the
end of the treatment, mechanical hypersensitivity was evaluated in
all the experimental groups of both strains, WKY (Figure 2A) and
SHR (Figure 2B), via paw pressure test on ipsilateral and
contralateral paw (1 h after the last treatment). Vehicle-treated
CCI animals presented an altered response to the noxious stimulus
on the ipsilateral paw, tolerating a bit more than half of control
weight; there was no significant difference in pain response
between the strains in all the experimental conditions. No
difference were reported between the left paw of vehicle-treated
CCI and SHAM group. A beneficial effect was observed with
repeated (+/−)-thioctic acid 250 μmol·kg−1·die−1 treatment (p 
0.0005), since it increased pain threshold of the ipsilateral paw of
CCI animals; treatment with the half dose of (+)-thioctic acid
produced the same positive effects (p  0.0004). Half dose of
racemic mixture induced a lower but however significant (p 
0.0008) improvement in pain sensitization. The analgesic activity
of both compounds was comparable to the outcomes of pregabalin
administrations; conversely, repeated treatment with
(−)-enantiomeric isoform of thioctic acid was not active. Similar
results were obtained repeating measurements 24 h after the last
administration of thioctic acid forms (data not shown).
Morphological Analysis: Sciatic Nerve
After the behavioral tests, animals were sacrificed, both sciatic
nerves and spinal cord tissue were explanted. Sciatic nerve sample
tissues were stained and processed: Mallory’s trichrome staining
FIGURE 1 | CONSORT flow diagram of the clinical study NESTIORADE (Sensory motor neuropathy of the sciatic nerve: Comparative assessment of the
effectiveness of racemic and dextrorotatory forms of thioctic acid).
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(Supplementary Figure S1); immunohistochemistry for
neurofilament (NF, Figure 3) and myelin basic protein (MBP,
Figure 4).
Mallory’s trichrome staining on CCI right sciatic nerve
highlighted a massive degeneration of myelinated and non-
myelinated axons distal to the ligation site both in WKY (data
not shown) and SHR rats (Supplementary Figure S1), induced by
constriction injury. In CCI SHR sciatic nerve, Mallory’s trichrome
staining of distal-to-ligation right sciatic nerve showed: a typical
Wallerian degeneration with less compact oedematous axons and
accumulation of inflammatory cells, absence or damage of myelin
sheaths and a scarcely identifiable myelin-axon border
(Supplementary Figure S1A). These changes were partly
inhibited only by the treatment with (+/−)-thioctic acid
250 μmol·kg−1·die−1 (Supplementary Figure S1C) and
(+)-thioctic acid (Supplementary Figure S1D). Administrations
of (+/−)-thioctic acid 125 μmol·kg−1·die−1 (Supplementary
Figure S1B) and (−)-thioctic acid (Supplementary Figure S1E)
left the morphology of damaged nerve unaltered. Pregabalin
injections (Supplementary Figure S1F), restored the morphology
of the nerve countering the reduction of axon and myelin thickness
in nerve fibers of the lesioned nerve.
FIGURE 2 | Paw pressure test. Paw pressure test on operated (CCI) and unoperated paws of WKY (A) and SHR (B) following treatment with
300 μmol·kg−1·die−1pregabalin, 250 and 125 μmol·kg−1·die−1 (+/−)-thioctic acid (t.a.), 125 μmol·kg−1·die−1 (+)- and (−)-thioctic acid or with vehicle (saline). Each
experimental group is n  6; data are expressed as mean ± SEM, in grams. **p < 0.01 vs the left unoperated paw value, ^̂p < 0.01 vs CCI + saline solution.
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Sections of sciatic nerve explanted from SHAM SHR were
processed for NF immunohistochemistry: they developed a dark
brown axonal staining, with a particularly intense
immunoreaction in the external part of axons (Figure 3A).
Reduced NF immunoreactivity was observed in the distal to
ligation sciatic nerve from control (untreated) CCI SHR rats
(Figure 3B) as also demonstrated by quantitative analysis,
expressed as Optical Density Unity (ODU) in the left-bottom
graph, that showed a significantly (p  0.0006) decrease of
quantitative immunoreaction (Figure 3, graph column B).
Only the treatment with (+)-thioctic acid augmented axonal
NF immunoreactivity in the distal part of the sciatic nerve in
a significant way (p  0.0025) (Figure 3, panel and graph column
E). MBP immunostaining showed a physiological pattern of
myelin organization in the SHAM operated rats, with dark
brown immunoreactivity in the myelin sheaths (Figure 4A).
As showed by quantitative analysis (Figure 4, left-bottom
graph), a remarkable reduction (p  0.0005) of MBP
immunoreactivity was evident in the distal part of the ligated
nerve (panel and graph column B). Treatment with racemic
thioctic acid 250 μmol·kg−1·die−1 (panel and graph column D)
and (+)-thioctic acid (panel and graph column E) significantly
raised MBP immunoreactivity (p  0.0003) in the distal part of
ligated nerve, while the other compounds produced no
improvements.
Morphological and Biochemical Analysis: Spinal Cord
In the spinal cord we investigated oxidative stress signals: the levels
of malondialdehyde (MDA) (Supplementary Figure S2), protein
carbonylation and 8-hydroxy-2′-deoxyguanosine (8-OHdG)
(Figure 5: i-ii and iii-iv, respectively).
SHAM non-hypertensive and hypertensive rats had similar
MDA levels, while a statistically significant raise (p  0.034) was
observed in the neuropathic SHR group (Supplementary Figure
S2, column C) in comparison to control SHAM SHR
(Supplementary Supplementary Figure S2, column B); all
treatments were unsuccessful at recovery.
Densitometry analysis (Figure 5ii) on blotted carbonylated
protein (Figure 5i), showed that SHAM-operatedWKY and SHR
(A, B bands/columns) displayed the same low level protein
FIGURE 3 | Sections of sciatic nerve processed for neurofilament immunohistochemistry. Treatments are indicated as follows: (A) SHAMSHR + saline solution; (B)
CCI SHR + saline solution; (C)CCI SHR + (+/−)-thioctic acid 125 μmol·kg−1·die−1; (D)CCI SHR + (+/−)- thioctic acid 250 μmol·kg−1·die−1; (E)CCI SHR + (+)- thioctic acid
125 μmol·kg−1·die−1; (F)CCI SHR + (−)-thioctic acid 125 μmol·kg−1·die−1; (G)CCI SHR + pregabalin 300 μmol·kg−1·die−1. Left-bottom graph represents a densitometric
analysis of the expression of neurofilament. Each experimental group is n  6; data, expressed as Optical Density Unit (ODU), are the mean ± SEM. Calibration bar:
10 μm *p < 0.05 vs SHAM SHR, p̂ < 0.05 vs CCI SHR + saline solution.
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oxidation, while CCI-induced neuropathy resulted in higher
carbonylated protein values in spinal tissue of CCI SHR
animals (C band/column). (+/−)-thioctic acid
250 μmol·kg−1·die−1 lowered carbonylated proteins to control
values (D band/column), the same result was gained by
dextrorotatory enantiomer administrations (F band/column)
and both treatments resembled pregabalin effects (H band/
column). Conversely, the treatment with (+/−)-thioctic acid
125 μmol·kg−1·die−1and with (−)-thioctic acid (E, G bands/
columns) lead to a very slight non-significant reduction of
protein oxidation. Expression of 8-OHdG in dorsal horns of
spinal cord was investigated through immunohistochemistry and
related densitometric analisys (Figure 5iii,iv). CCI SHR rats
(panel/column C-bis) spinal cord displayed more pronounced
levels (p  0.028) of 8-OHdG as compared to SHAM WKY and
SHR rodents’ spinal cord (panel/column A and B, respectively),
markedly in the cell body neurons of dorsal horns. Treatments
with almost all forms of thioctic acid induced an antioxidant
effect (panel/column D, E, F), only (−)-thioctic acid (panel/
column G) injections produced no amelioration, similarly to
pregabalin (panel/column H).
In addition, we evaluated the neuroprotective effects of
thioctic acid from ex-vivo analysis on the spinal cord (Figures
6i–6ii). Dorsal horn sections were probed with GFAP antibody
(Figure 6i): the number of GFAP-positive cells was comparable
between SHAM SHR and WKY rats (panels A and B), therefore
we moved on the analysis of SHR animals. Sciatic nerve ligation
induced an activation of astrocytes with high production of GFAP
and ramified branches (panel C), while treating with
(+/−)-thioctic acid 250 μmol·kg−1·die−1 restored the
physiological state (panel D). Injections with (+)-thioctic acid
(panel F) reproduced the same result of double-concentrated
racemic compound (panel D); conversely, an opposite effect was
obtained by the treatment with 125 μmol·kg−1·die−1 racemic
compound and (−)-enantiomer (panel E and G, respectively).
A pattern of activated astrocytes was also observed in the spinal
cord of pregabalin treated rats (panel H). These observations were
confirmed by the analysis of mean area (μm2) of GFAP-
immunopositive astrocytes, from both dorsal and ventral
horns (Figure 6ii). No significant differences between the two
regions were noticeable in each experimental group. In the dorsal
horn, sham WKY and SHR rats presented the same quantity of
immunoreactive tissue while CCI SHR animals had 30% more
GFAP-positive tissue. Treatments with (+/−)-thioctic acid
250 μmol·kg−1·die−1 (p  0.005 vs. CCI) and (+)-enantiomer
125 μmol·kg−1·die−1 (p  0.032 vs. CCI) reduced the area
almost to non-neuropathic values, while glial activation was
confirmed in groups treated with 125 μmol·kg−1·die−1 racemic
FIGURE 4 | Sections of sciatic nerve processed for myelin basic protein (MBP) immunohistochemistry. Treatments are indicated as follows: (A) SHAMSHR + saline
solution; (B) CCI SHR + saline solution; (C) CCI SHR + (+/−)-thioctic acid 125 μmol·kg−1·die−1; (D) CCI SHR +(+/−)-thioctic acid 250 μmol·kg−1·die−1; (E) CCI SHR +
(+)-thioctic acid 125 μmol·kg−1·die−1; (F)CCI SHR + (−)-thioctic acid 125 μmol·kg−1·die−1; (G)CCI SHR + pregabalin 300 μmol·kg−1·die−1. Left-bottom graph represents
a densitometric analysis of the expression of myelin basic protein. Each experimental group is n  6; data, expressed as Optical Density Unit (ODU), are the mean ±
SEM. Calibration bar: 10 μm *p < 0.05 vs SHAM SHR, p̂ < 0.05 vs CCI SHR + saline solution.
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thioctic acid, (−)-enantiomer and pregabalin. In the ventral horn
the pattern is the same.
Clinical Results
Neuropathy Symptoms and Change (NSC) Parameter
Initial (baseline) values for theNSC scale averaged 17.2± 5.1 inGroup
1 patients (+/−)-thioctic acid and 17.6 ± 5.3 in Group 2 patients
(+)-thioctic acid. After 60 days of treatment, these values decreased to
13.0 ± 5.4 in group 1 patients and 11.3 ± 4.8 in group 2 patients
(Table 2). This reduction was statistically significant vs. baseline for
both treatments (respectively p  0.0000 and p  0.0000 for the two
groups at the two-sided Student’s t test for paired data). The average
reduction for this scale was of 4.12 ± 3.13 points for patients of Group
1 and 6.26 ± 4.30 points for patients of Group 2 (Table 2) (p  0.0003,
ANOVA). (Supplementary Figure S3A). Values of the NSC scale
were also used to assess the percentage change compared to the
starting value. Percentage changes resulted to be of 24.7 ± 17.3% in
Group 1 patients and 34.4 ± 19.1% in Group 2 patients (Table 2) (p 
0.009, ANOVA). To analyze the different treatment over time a two
way ANOVA for repeated measure was performed: data showed
significative results for the model (p  0.0000) and for the time (p 
0.0000) and treatment (p  0.048) parameters.
Neuropathic Injury Score Parameter
Initial (baseline) average values for the NIS scale were 4.30 ±
3.08 in Group 1 patients and 4.28 ± 4.22 in Group 2 patients.
After 60 days of therapy, values decreased to 2.64 ± 2.99 in
Group 1 patients and 1.94 ± 3.80 in Group 2 patients
(Table 2). This reduction was statistically significant vs.
baseline for both treatments (p  0.0000 for both groups at
two sided Student’s t test for paired data). The average
reduction in the scale was of 1.66 ± 1.81 points in Group
1 patients and 2.34 ± 2.56 points for Group 2 patients
(Table 2). This reduction did not reach statistical
significance at the ANOVA (p  0.308). (Supplementary
Figure S3B). Values of NIS were also evaluated in terms
of percent reduction compared to the starting value: the
decrease, which averaged 40.2 ± 43.3% in Group 1 patients
and 53.9 ± 44.4% in Group 2 patients (Table 2), was not
statistically significant (p  0.121). Results of the two way
FIGURE 5 | Oxidative stress status in the spinal cord (lumbar region L5). Carboxylated proteins blotting of the spinal cord (i) and its densitometric analysis (ii).
Sections of dorsal horns of spinal cord (lumbar region L5) processed for immunohistochemistry of 8-OHdG (iii) and densitometric analysis (iv). Calibration bar of iii): A-C
200 μm; Cbis-H: 25 μm; densitometric analysis was performed on 25 μm calibration bar-images. In all panels, treatments are indicated as follows: (A) SHAM WKY +
saline solution; (B) SHAM SHR + saline solution; C, Cbis) CCI SHR + saline solution; (D) CCI SHR + (+/−)-thioctic acid 250 μmol·kg−1·die−1; (E) CCI SHR +
(+/−)-thioctic acid 125 μmol·kg−1·die−1; (F) CCI SHR + (+)-thioctic acid 125 μmol·kg−1·die−1; (G) CCI SHR + (−)-thioctic acid 125 μmol·kg−1·die−1; (H) CCISHR +
Pregabalin 300 μmol·kg−1·die−1. Data are expressed as mean ± SEM. *p < 0.05 vs SHAM SHR + saline solution; p̂ < 0.05 vs CCI SHR + saline solution.
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ANOVA for repeated measure showed significative results for
the model (p  0.0000) and for the time (p  0.0000) but not
significative for treatment (p  0.474) parameter.
Neuropathy Total Symptom Score-6 (NTSS-6)
Parameter
Initial (baseline) average values for the NTSS-6 scale were 4.01 ±
2.56 in Group 1 patients and 3.86 ± 2.95 in Group 2 patients.
After 60 days of treatment these values decreased to 2.65 ± 2.36 in
Group 1 patients and 1.98 ± 2.47 in Group 2 patients (Table 2).
This reduction was statistically significant vs. baseline for both
treatments (p  0.0000 for both groups at two sided Student’s
t test for paired data). The average reduction in the scale was of
1.35 ± 1.95 points for Group 1 patients and 1.88 ± 1.96 points for
Group 2 patients (Table 2). This decrease was not significant at
the ANOVA analysis (p  0.165). (Supplementary Figure S3C).
Data were also evaluated as percent reduction compared to the
baseline: this analysis resulted in the 36.2 ± 39.7% in the Group 1
patients and in the 53.7 ± 40.2% in the Group 2 patients (Table 2)
(p  0.031, ANOVA). Results of the two way ANOVA for
repeated measure showed significative results for the model
(p  0.0000) and for the time (p  0.0000) but not
significative for treatment (p  0.264) parameter.
Quality of Life
Both treatment with thioctic acid were safe, no patients
withdrawn from study; of the 107 patients considered, 7 did
not meet the inclusion criteria (first manifestation, presentation
before 40 days). Of the patients only one experienced side effects
after about a month of treatment, with loss of taste and a sense of
bitterness in the mouth. The manifestation was considered a
“possible” side effect, but did not lead to discontinuation of
therapy and ended before the last visit of the study.
Considered quality of life criteria included the response rate to
therapy, the half-lives of pain, changes in sleep quality and
changes in painkillers assumption. As to NSC parameter, the
response rate to therapy was 84% in Group 1 patients
(+/−)-thioctic acid and 94% in Group 2 patients (+)-thioctic
acid. As to NIS parameter, the response was positive in 60% of
patients of Group 1 and in 66% patients of Group 2. For NTSS-6
scale, a positive response to therapy was observed in 64% patients
of Group 1 and in 78% patients of Group 2 (Table 3).
Half-life of pain, representing the time during which the
parameters were considered, reached half of the initial value:
for NSC it was 125 days in Group 1 patients and 84 days in Group
2 patients with a 32% reduction for (+)-thioctic acid as compared
to (+/−)-thioctic acid. The half-life parameter for NIS was 78 days
FIGURE 6 | Astrocytes activation: GFAP immunohistochemistry in spinal cord. Sections of dorsal horn of spinal cord (images A-H, i) processed for the
immunohistochemistry of glial fibrillary acid protein (GFAP) and densitometric analysis (ii) of the mean immunoreaction area in both dorsal and ventral horns. In all panels,
treatments are indicated as follows: (A) SHAMWKY + saline solution; (B) SHAM SHR + saline solution; (C) CCI SHR + saline solution; (D) CCI SHR + (+/−)-thioctic acid
250 μmol·kg−1·die−1; (E) CCI SHR + (+/−)-thioctic acid 125 μmol·kg−1·die−1; (F) CCI SHR + (+)-thioctic acid 125 μmol·kg−1·die−1; (G) CCI SHR + (−)-thioctic acid
125 μmol·kg−1·die−1; (H) CCI SHR + Pregabalin 300 μmol·kg−1·die−1. Calibration bar: 25 μm. Data are expressed as mean ± SEM; *p < 0.05 vs SHAM SHR + saline
solution; p̂ < 0.05 vs CCI SHR + saline solution.
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in Group 1 patients and 55 days in Group 2 patients, with a 29%
reduction for (+)-thioctic acid as compared to (+/−)-thioctic acid.
Assessment of half-lives for the scale NTSS-6 resulted in 86 days
in Group 1 patients and 62 days in Group 2 patients, with a
reduction of 29% in favor of (+)-thioctic acid (Table 3).
Assessment of sleep quality showed in Group 1 patients a 48% of
sleep improvement, a 50% of lack of difference and a 2%of worsening.
In Group 2 patients, a 66% of sleep improvement, a 34% of no
differences and no cases of worsening were reported (Table 3).
Analysis of the need to add painkiller to the antioxidant-based
therapy revealed in Group 1 patients a reduction of analgesics
intake in 58% of individuals, no changes in 40% of them and an
increase in 2% of subjects. In Group 2, 72% of patients reduced
the use of painkillers, which remained unchanged in 26% of cases.
In 2% of examined patients, analgesic medication was increased
(Table 3).
Gender Influence Evaluation
The stratification of data by gender showed that the groups were
mostly homogeneous in the distribution with regard to both sex
and age (Group 1: 24 female, mean age 53.0 ± 10.0; 26 male, mean
age 53.5 ± 12.5; Group 2: 27 female, mean age 54.6 ± 11.4; 23
male, mean age 52.7 ± 11.4)
The analysis performed by two-way ANOVA for repeated data
considering the variables of sex and treatment showed at the end
of the study that none of the three pain parameters considered
were influenced by the sex of the participants. (NSC: overall value
p  0.006, treatment p  0.005, gender p  0.172; NIS: overall value
TABLE 2 | Neuropathy Symptoms and Change scale (NSC), Neuropathy Impairment Score (NIS) and Neuropathy Total Symptom Score-6 (NTSS-6) in Group 1 patients
[(+/−)-thioctic acid)] and in Group 2 patients [(+)-thioctic acid] at baseline (T0) and after 60 days of treatment (Tlast).Data aremeans ± S.D. Response rate and pain half-life
data represent the percentage of patients with reduction of pain score respect to baseline after treatment (response ratio) and the days for pain half-life.
Neuropathy symptoms and change scale (NSC), neuropathy impairment score (NIS) and neuropathy total symptom Score-6 (NTSS-6)




NCS T0 17.6 ± 5.3 17.2 ± 5.1
Tlast 11.3 ± 4.8*# 13.0 ± 5.4*
Reduction from baseline 6.26 ± 4.30# 4.12 ± 3.13
Percentage reduction 34.4 ± 19.1# 24.7 ± 17.3
Response rate 94° 84
Pain half-life 84 125
NIS T0 4.28 ± 4.22 4.30 ± 3.08
Tlast 1.94 ± 3.80* 2.64 ± 2.99*
Reduction from baseline 2.34 ± 2.56 1.66 ± 1.81
Percentage reduction 53.9 ± 44.4 40.2 ± 43.3
Response rate 66 60
Pain half-life 55 78
NTSS-6 T0 3.86 ± 2.95 4.01 ± 2.56
Tlast 1.98 ± 2.47* 2.65 ± 2.36*
Reduction from baseline 1.88 ± 1.96 1.35 ± 1.95
Percentage reduction 53.7 ± 40.2# 36.2 ± 39.7
Response rate 78° 64
Pain half-life 62 89
*p < 0.05 vs T0 evaluated by Student’s t-test for paired data; #p < 0.05 vs Group 1 patients evaluated by ANOVA Test; ° p < 0.05 vs. Group 1 patients, X2 test.
TABLE 3 | Sleep quality and pain killer intake variations in Group 1 [(+/−)-thioctic acid)] and in Group 2 [(+)-thioctic acid]. Data shown represent the absolute number and the
percentage of patients.
Sleep quality and pain killer intake variations
Quality of life Group 2 Group 1
(+)-thioctic acid (+/−)-thioctic acid Significance at the X squared test
Quality of sleep
Improved 33 (66%) 24 (48%) p  0,00,097
Unchanged 17 (34%) 25 (50%)
Worsened 0 (0%) 1 (2%)
Painkiller intake
Increased 1 (2%) 1 (2%) p  0,01,593
Unchanged 13 (26%) 20 (40%)
Reduced 36 (72%) 29 (58%)
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p  0.403, treatment p  0.335, gender p  0.377; NTSS-6: overall
value p  0.379, treatment p  0.171, gender p  0.876).
DISCUSSION
Low back pain is becoming one of the most common diseases in
industrialized countries, due to inappropriate postural attitudes
and sedentary lifestyles: more than 70% of individuals are
estimated to suffer of low back pain at least one time in their
life (Baron et al., 2016); it is the fifth reason for medical
consultation in the United States (U.S.) and about a quarter of
U.S. adults experienced low back pain for at least one whole day
over a period of three months (Deyo et al., 2006). The guidelines
of the European Federation of Neurological Societies (EFNS) and
of the International Association for the Study of Pain (IASP) have
been considering the use of different classes of drugs, such as
analgesics, antidepressants and anticonvulsants, for the treatment
of neuropathic pain (Dworkin et al., 2007; Attal et al., 2010).
A proper treatment of low back pain should not only control pain,
but also maintain/restore nerve function. Oxidative stress reduces
neuronal function and local blood flow, limiting the arrival of
nutrients to nerve cells (Mitsui et al., 1999; Memeo and Loiero,
2008). Antioxidant products, therefore, could contribute to control
symptoms and act on the pathogenesis as well (Ranieri et al., 2009).
Thioctic acid is a natural fatty acid endogenously produced by
mammalian cells and chemically existing as two optical isomers. It
is an essential component of some mitochondrial enzyme complexes,
important in the glucose metabolism (de Arriba et al., 2003) and able
to actively counter various forms of oxidative stress (Tibullo et al.,
2017). The dextrorotatory enantiomer is better recognized by enzymes
(Streeper et al., 1997) and maximum plasma concentration (Cmax) is
approximately 40–50% higher with (+)-thioctic acid than with
(+/−)-thioctic acid at the same dose (Carlson et al., 2007).
Preclinical experiments on CCI-SHR showed that following
a 15-days cure with thioctic acid (racemic form, dextrorotary
and levorotary enantiomers), neuropathic hypertensive rats
ameliorated their altered algesic sensitivity and oxidative stress
levels. Moreover, the treatment with (+)-enantiomer was as
effective as with double-concentrated racemic (+/−)-thioctic
acid and the nociceptive threshold closely reached that
obtained by administrating pregabalin; on the contrary, the
levorotatory enantiomer alone was as ineffective as injecting
the saline solution. All these data suggested a prominently
active role of the dextrorotatory enantiomer in the racemic
mixture. Accordingly, previous studies on chemotherapy-
induced neuropathy described similar results: thioctic acid
acutely dosed to vincristine-treated rats reversed allodynia
symptoms; chronic injections of 15, 30, and 60 mg/kg of
(+/−)-thioctic acid on neuropathic rodents, which were
given paclitaxel, significantly reduced mechanical and cold
allodynia (Kahng et al., 2015; Sun et al., 2019). As previously
reported (Tomassoni et al., 2013), SHR rats showed higher
values of systolic blood pressure as compared to WKY rats.
CCI did not induce an increase of blood pressure values, nor
different formulations of racemic and enantiomer thioctic acid
affected blood pressure values in SHR. These results
demonstrated that the analgesic and neuroprotective effects
of thioctic acid was not mediated by a decrease of systolic
blood pressure (Tomassoni et al., 2013).
Microanatomical analysis of this study revealed changes
after loose ligation of the sciatic nerve: either axonal
components of the nerve and myelin sheaths were affected,
involving myelinated and unmyelinated nerve fibers. These
findings support and extend previous studies reporting the
degeneration of axonal components and myelin sheaths, with
decrease of NF and MBP in the portion of nerve which is distal
to the ligation (Di Cesare Mannelli et al., 2009; Tomassoni
et al., 2018).
Thioctic acid, above all the (+)-enantiomer form, exerted a
protective activity on the peripheral nerve portion affected by
ligation, not shared by pregabalin. We would suppose that
amelioration of hyperalgesia after treatment may partly depend
on the effects that thioctic acid induced on sciatic nerve
morphology, due to the antioxidant ability to scavenge and
inactivate free radicals. Its supplementation as natural antioxidant
has already demonstrated multiple beneficial effects (Tibullo et al.,
2017) and (+)-thioctic acid showed the most pronounced activity.
Studies about the mechanisms of neuropathic pain
following injury of peripheral nerves demonstrated that
nerve damage was related to altered neuronal plasticity and
aberrant function of glial cells in the lumbar spinal cord
(Cirillo et al., 2015; De Luca et al., 2016). These neuroglial
plastic changes induce both neuronal/astrocytic activation and
alteration of neuroglial interactions, determining maladaptive
synaptic plasticity in the spinal somatosensory system, which
seems to be directly responsible for the neuronal
hyperexcitability and the enhanced synaptic transmission
that sustain neuropathic pain (Gwak and Hulsebosch, 2009;
Wang et al., 2009).
As previously demonstrated (Cirillo et al., 2011, Cirillo
et al., 2012; Colangelo et al., 2012), our evidence confirms
that in the lumbar spinal cord CCI is associated with reactive
gliosis, characterized by hypertrophy of astrocytes and their
activation, and with an increase of oxidative stress phenomena
in the somatosensory neurons of the dorsal horn. Here, the
beneficial effects of thioctic acid were related to its antioxidant
properties, like the ability to restore the intrinsic antioxidant
systems, supporting their production or cell accessibility (Shay
et al., 2009; Goraca et al., 2011; Salehi et al., 2019). The
compound, in particular its dextrorotatory enantiomer,
lowered the oxidation status of proteins and the expression
of 8-OHdG in the somatosensory neurons of the dorsal horn: it
might be, in a positive loop, linked to effects on astrocytes cells,
since treatments with dextrorotatory enantiomer and double-
concentrated racemic formulation reduced size of astrocytes
and GFAP expression.
These data from spinal cord could explain the protection of
(+)-thioctic acid on the brain. In a previous study we indicated,
after mono-lateral CCI of sciatic nerve, augmented GFAP
expression mainly in the gray matter of sensory cortex and
decreased NF expression as a consequence of nerve damage;
we also showed that treatment with antioxidants, but not with
pregabalin, prevented to some extent astrogliosis and neuronal
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damage in cerebral cortex, similarly to the present findings in
spinal cord (Tomassoni et al., 2013).
Encouraged by the findings of the preclinical study, which
pointed out a more prominent activity of (+)-thioctic acid as
compared to the other tested forms of thioctic acid,
resembling or even exceeding the efficacy of pregabalin, a
clinical study was set up (using a dosage comparable to the
preclinical evaluation, Reagan-Shaw et al. (2008) and Nair
and Jacob (2016). The results of the clinical study confirmed
the efficacy of the antioxidant thioctic acid in the treatment of
the peripheral neuropathy without differences in male and
female (Memeo and Loiero, 2008; Ranieri et al., 2009;
Agathos et al., 2018; Mrakic-Sposta et al., 2018; Salehi
et al., 2019; Passiatore et al., 2020) being also
characterized by good safety profile which makes it
suitable for prolonged treatment even in the chronic phase
of this disease (Ametov et al., 2003; Ziegler et al., 2006).
Anyway, it should be carefully prescribed and monitored
since the possibility of side effects as recently emerged in a
preclinical toxicologic study (Lucarini et al., 2020). The
results of clinical study show a greater effectiveness of
(+)-thioctic acid compared to (+/−)-thioctic acid in terms
of major impact on pain symptoms, rapidity of therapeutic
effects onset and, more generally, better quality of life, as
confirmed by the response rate to therapy. Our results are
consistent with the effects observed in the same period of
time (60 days) in other studies (Mrakic-Sposta et al., 2018;
Passiatore et al., 2020), even if with minor side effects with
respect to those observed in patients treated with a dose
higher than 600 mg/day (Mrakic-Sposta et al., 2018). The
advantage in using (+)-thioctic acid, as compared to the
racemic form, may be related to an increased
bioavailability of this enantiomer, that boosts its
antioxidant activity (Maglione et al., 2015) as well as to
higher biological activity. Preclinical and clinical evidences
suggest positive properties of thioctic acid in the treatment of
low back pain with a more relevant efficacy of (+)-thioctic
acid compared to (+/−)-thioctic acid on pain, on time of onset
of therapeutic effects and on quality of life of patients
suffering from the symptoms under study. These
observations are worthy of further analysis, but they make
it a good candidate for treatment of low back pain.
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Gorąca, A., Huk-Kolega, H., Piechota, A., Kleniewska, P., Ciejka, E., and Skibska, B.
(2011). Lipoic acid - biological activity and therapeutic potential. Pharmacol.
Rep. 63 (4), 849–858. doi:10.1016/s1734-1140(11)70600-4
Gwak, Y. S., and Hulsebosch, C. E. (2009). Remote astrocytic and microglial
activation modulates neuronal hyperexcitability and below-level neuropathic
pain after spinal injury in rat. Neuroscience 161 (3), 895–903. doi:10.1016/j.
neuroscience.2009.03.055
Kahng, J., Kim, T. K., Chung, E. Y., Kim, Y. S., and Moon, J. Y. (2015). The effect of
thioctic acid on allodynia in a rat vincristine-induced neuropathy model. J. Int.
Med. Res. 43 (3), 350–355. doi:10.1177/0300060515569287
Leighton, G. E., Rodriguez, R. E., Hill, R. G., and Hughes, J. (1988). kappa-Opioid
agonists produce antinociception after i.v. and i.c.v. but not intrathecal
administration in the rat. Br. J. Pharmacol. 93 (3), 553–560. doi:10.1111/j.
1476-5381.1988.tb10310.x
Lokhandwala, M. F. (2010). “Acido tioctico : farmacologia ed applicazioni
terapeutiche di un antiossidante particolare,” in R(+) Dalla Ricerca di Base
alle Applicazioni Cliniche dell’Enantiomero Naturale di un Antiossidante
Multifunzionale. Editor F. Amenta, V. Costigliola, and M. F. Lokhandwala
(Pisa, Italy: Pacini Editore S.p.A), 7–15.
Lucarini, E., TralloriTomassoni, E. D., Amenta ì, F., Ghelardini, C., Pacini, A., and
Di Cesare Mannelli, L. (2020). Toxicological profile of the pain-relieving
antioxidant compound thioctic acid in its racemic and enantiomeric forms.
Antioxidants 9 (8), 749. doi:10.3390/antiox9080749
Maglione, E., Marrese, C., Migliaro, E., Marcuccio, F., Panico, C., Salvati, C.,
et al. (2015). Increasing bioavailability of (R)-alpha-lipoic acid to boost
antioxidant activity in the treatment of neuropathic pain. Acta Biomed. 86
(3), 226–233.
Memeo, A., and Loiero, M. (2008). Thioctic acid and acetyl-L-carnitine in the
treatment of sciatic pain caused by a herniated disc: a randomized, double-
blind, comparative study. Clin. Drug Invest. 28 (8), 495–500. doi:10.2165/
00044011-200828080-00004
Mitsui, Y., Schmelzer, J. D., Zollman, P. J., Mitsui, M., Tritschler, H. J., and Low, P. A.
(1999). Alpha-lipoic acid provides neuroprotection from ischemia-reperfusion
injury of peripheral nerve. J. Neurol. Sci. 163 (1), 11–16. doi:10.1016/s0022-
510x(99)00017-9
Mrakic-Sposta, S., Vezzoli, A., Maderna, L., Gregorini, F., Montorsi, M., Moretti, S.,
et al. (2018). R(+)-Thioctic acid effects on oxidative stress and peripheral
neuropathy in type II diabetic patients: preliminary results by electron
paramagnetic resonance and electroneurography. Oxid. Med. Cell. Longev.
2018, 1767265. doi:10.1155/2018/1767265
Nair, A. B., and Jacob, S. (2016). A simple practice guide for dose conversion
between animals and human. J. Basic Clin. Pharm. 7 (2), 27–31. doi:10.4103/
0976-0105.177703
Oyenihi, A. B., Ayeleso, A. O., Mukwevho, E., and Masola, B. (2015). Antioxidant
strategies in the management of diabetic neuropathy. BioMed. Res. Int. 2015,
515042. doi:10.1155/2015/515042
Packer, L., Witt, E. H., and Tritschler, H. J. (1995). alpha-Lipoic acid as a biological
antioxidant. Free Radic. Biol.Med. 19 (2), 227–250. doi:10.1016/0891-5849(95)00017-r
Passiatore, M., Perna, A., De-Vitis, R., and Taccardo, G. (2020). The use of alfa-
lipoic acid-R (ALA-R) in patients with mild-moderate carpal tunnel syndrome:
a randomised controlled open label prospective study. Malaysian Orthop. J. 14
(1), 1–6. doi:10.5704/MOJ.2003.001
Pinto, R. Z., Maher, C. G., Ferreira, M. L., Ferreira, P. H., Hancock, M., Oliveira, V.
C., et al. (2012). Drugs for relief of pain in patients with sciatica: systematic
review and meta-analysis. BMJ 344, e497. doi:10.1136/bmj.e497
Ranieri,M., Sciuscio,M., Cortese, A.M., Santamato, A., Di Teo, L., Ianieri, G., et al. (2009).
The use of alpha-lipoic acid (ALA), gamma linolenic acid (GLA) and rehabilitation in
the treatment of back pain: effect on health-related quality of life. Int. J. Immunopathol.
Pharmacol. 22 (Suppl 3), 45–50. doi:10.1177/03946320090220s309
Reagan-Shaw, S., Nihal, M., and Ahmad, N. (2008). Dose translation from animal
to human studies revisited. Faseb. J. 22 (3), 659–661. doi:10.1096/fj.07-9574LSF
Riego, G., Redondo, A., Leánez, S., and Pol, O. (2018). Mechanism implicated in the anti-
allodynic and anti-hyperalgesic effects induced by the activation of heme oxygenase 1/
carbon monoxide signaling pathway in the central nervous system of mice with
neuropathic pain. Biochem. Pharmacol. 148, 52–63. doi:10.1016/j.bcp.2017.12.007
Salehi, B., Berkay Yilmaz, Y., Antika, G., Boyunegmez Tumer, T., Fawzi
Mahomoodally, M., Lobine, D., et al. (2019). Insights on the use of alpha-
lipoic acid for therapeutic purposes. Biomolecules 9. doi:10.3390/
biom9080356
Schnitzer, T. J., Ferraro, A., Hunsche, E., and Kong, S. X. (2004). A comprehensive
review of clinical trials on the efficacy and safety of drugs for the treatment of
low back pain. J. Pain Symptom Manage. 28 (1), 72–95. doi:10.1016/j.
jpainsymman.2003.10.015
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 60757214
Pacini et al. (+)-Thioctic Acid Against Neuropathic Pain
Shay, K. P.,Moreau, R. F., Smith, E. J., Smith, A. R., andHagen, T.M. (2009). Alpha-lipoic
acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Biochim. Biophys. Acta 1790 (10), 1149–1160. doi:10.1016/j.bbagen.2009.07.026
Streeper, R. S., Henriksen, E. J., Jacob, S., Hokama, J. Y., Fogt, D. L., and Tritschler,
H. J. (1997). Differential effects of lipoic acid stereoisomers on glucose
metabolism in insulin-resistant skeletal muscle. Am. J. Physiol. Endocrinol.
Metab. 273 (1), E185–E191. doi:10.1152/ajpendo.1997.273.1.E185
Sun, H., Guo, X., Wang, Z., Wang, P., Zhang, Z., Dong, J., et al. (2019). Alphalipoic
acid prevents oxidative stress and peripheral neuropathy in nab-paclitaxel-
treated rats through the Nrf2 signalling pathway.Oxid. Med. Cell. Longev. 2019,
1–11. doi:10.1155/2019/3142732
Tayebati, S. K., Martinelli, I., Moruzzi, M., Amenta, F., and Tomassoni, D. (2017).
Choline and choline alphoscerate do not modulate inflammatory processes in
the rat brain, Nutrients, 9 (10), 1084. doi:10.3390/nu9101084
Tayebati, S. K., Tomassoni, D., and Amenta, F. (2012). Spontaneously hypertensive
rat as a model of vascular brain disorder: microanatomy, neurochemistry and
behavior. J. Neurol. Sci. 322 (1-2), 241–249. doi:10.1016/j.jns.2012.05.047
Tibullo, D., Li Volti, G., Giallongo, C., Grasso, S., Tomassoni, D., Anfuso, C. D.,
et al. (2017). Biochemical and clinical relevance of alpha lipoic acid: antioxidant
and anti-inflammatory activity, molecular pathways and therapeutic potential.
Inflamm. Res. 66 (11), 947–959. doi:10.1007/s00011-017-1079-6
Tomassoni, D., Amenta, F., Di Cesare Mannelli, L., Ghelardini, C., Nwankwo, I. E.,
Pacini, A., et al. (2013). Neuroprotective activity of thioctic acid in central
nervous system lesions consequent to peripheral nerve injury. BioMed. Res. Int.
2013, 1–14. doi:10.1155/2013/985093
Tomassoni, D., Di Cesare Mannelli, L., Bramanti, V., Ghelardini, C., Amenta, F., and
Pacini, A. (2018). Treatment with acetyl-L-carnitine exerts a neuroprotective effect
in the sciatic nerve following loose ligation: a functional andmicroanatomical study.
Neural Regener. Res. 13 (4), 692–698. doi:10.4103/1673-5374.230297
Vasdev, S., Ford, C. A., Parai, S., Longerich, L., and Gadag, V. (2000). Dietary α-lipoic
acid supplementation lowers blood pressure in spontaneously hypertensive rats.
J. Hypertens. 18 (5), 567–573. doi:10.1097/00004872-200018050-00009
Wang, W., Wang, W., Mei, X., Huang, J., Wei, Y., Wang, Y., et al. (2009). Crosstalk
between spinal astrocytes and neurons in nerve injury-induced neuropathic
pain. PLoS One 4 (9), e6973. doi:10.1371/journal.pone.0006973
Xiong, Q., Lu, B., Ye, H., Wu, X., Zhang, T., and Li, Y. (2015). The diagnostic value
of neuropathy symptom and change score, neuropathy impairment score and
Michigan neuropathy screening instrument for diabetic peripheral neuropathy.
Eur. Neurol. 74 (5-6), 323–327. doi:10.1159/000441449
Xu, L., Zhang, Y., and Huang, Y. (2016). Advances in the treatment of
neuropathic pain. Adv. Exp. Med. Biol. 904, 117–129. doi:10.1007/978-
94-017-7537-3_9
Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., et al. (2006).
Oral treatment with alpha-lipoic acid improves symptomatic diabetic
polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29 (11), 2365–2370.
doi:10.2337/dc06-1216
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Pacini, Tomassoni, Trallori, Micheli, Amenta, Ghelardini, Di
Cesare Mannelli and Traini. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 60757215
Pacini et al. (+)-Thioctic Acid Against Neuropathic Pain
